31st Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium 2019

30-day mortality rates post-TAVR halved in 10 years

Elvira Manzano, 20191029141200

The 30-day mortality rates among patients undergoing transcatheter aortic valve replacement (TAVR) have decreased by more than half over the last decade, with significant differences between genders, a CENTER* collaboration analysis has shown.

No increase in thrombus formation after aspirin withdrawal from ticagrelor-aspirin regimen

Roshini Claire Anthony, 20191017140101

The antithrombotic potency of ticagrelor alone on ex vivo whole blood thrombogenicity does not differ from that of ticagrelor plus aspirin in high-risk patients who have undergone percutaneous coronary intervention (PCI), according to the thrombogenicity substudy of the TWILIGHT* trial.

Onyx ONE: Polymer-based DES noninferior to polymer-free stent with short DAPT in high-bleeding risk patients

Pearl Toh, 20191016190000

In patients with high-bleeding risk, undergoing PCI* with a polymer-based drug-eluting stent (DES) was noninferior to a polymer-free drug-coated stent (DCS) when followed by a 1-month dual antiplatelet therapy (DAPT), according to the Onyx ONE** trial presented at TCT 2019.

PARTNER 3: TAVR benefit persists at 1 year in low-risk patients with severe AS

Elaine Soliven, 20191014000000

In low-risk patients with severe aortic stenosis (AS), those treated with transcatheter aortic valve replacement (TAVR) had a significantly better disease-specific health status at 1 year compared with those who received surgical aortic valve replacement (SAVR), according to the PARTNER 3* trial presented at TCT 2019.

Similar outcomes between ticagrelor, aspirin post-PCI

Audrey Abella, 20191010074844

Subgroup analyses of the GLOBAL LEADERS study showed similar treatment effects between ticagrelor and aspirin monotherapy following percutaneous coronary intervention (PCI) in patients with impaired renal function (IRF)* and diabetes.

Podcast: Prof Roxana Mehran stresses that ticagrelor monotherapy significantly reduces bleeding without increasing ischaemic events in TWILIGHT

20191010012346

Podcast: Prof Roxana Mehran stresses that ticagrelor monotherapy significantly reduces bleeding without increasing ischaemic events in TWILIGHT

Abbreviated dual antiplatelet therapy courses still effective

Tristan Manalac, 20191009110000

Shorter courses of dual antiplatelet therapy do not perform worse than longer regimens, according to a recent study presented at the 31st Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019).

TAVR as good as surgery in intermediate-risk patients with severe AS

Jairia Dela Cruz, 20191009090000

Patients with severe aortic stenosis and intermediate surgical risk may benefit from either transcatheter (TAVR) or surgical aortic valve replacement (SAVR) through 5 years of follow-up, according to midterm data from the PARTNER 2A trial presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

Highlights from the 31st Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium 2019

20191009063656

Highlights from the 31st Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium 2019

COAPT at 3 years: Sustained HHF reduction with mitral-valve repair over medical therapy

Roshini Claire Anthony, 20191008140101

The efficacy of transcatheter mitral-valve repair with the MitraClip device plus guideline-directed medical therapy (GDMT) over GDMT only in reducing hospitalizations for heart failure (HHF) among patients with HF and secondary mitral regurgitation (MR) was sustained at 3 years, including in patients who crossed over from GDMT alone at 2 years, updated results of the COAPT* trial show.